Should CSL (ASX:CSL) be your next dividend share?

Should CSL Limited (ASX: CSL) be your next ASX dividend share? The 1.04% yield may look paltry, but sometimes it's the growth that counts.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) has never had much of a reputation as an ASX dividend share. Especially when compared to its companions in the upper echelons of the S&P/ASX 200 Index (ASX: XJO). Think about it. CSL is now the third-largest ASX 200 share by market capitalisation. Gold and silver go to Commonwealth Bank of Australia (ASX: CBA) and BHP Group Ltd (ASX: BHP). And below CSL are the other 3 remaining big banks.

All of these other companies are (or at least were, pre-COVID) dividend heavyweights.

And yet CSL has never enjoyed such a reputation. Even today, the company offers a trailing dividend yield of 1.04% – not really 'set the world on fire' stuff. And that's not even following a COVID-induced dividend cut from last year. In fact, 2020 saw CSL dole out its highest dividends in history with a combined US$2.02 per share payout. 2021 so far has seen an interim dividend of US$1.04 per share, healthily exceeding 2020's interim dividend of 95 cents.

A man happily kisses a $50 note scrunched up in his hands representing the best ASX dividend stocks in Australia today

Image source: Getty Images

CSL's dividend growth

CSL has been around in some form for over a hundred years. But it only paid its first dividends in 2013. That was a combined payment of US$1.02 per share. That means that CSL has grown its annual dividend since 2013 by a compounded annual growth rate of 10.25% per annum.

Here's an interesting number for you. Back in October 2013, when CSL paid its first final dividend, CSL shares were going for roughly $66 apiece. Using today's exchange rate, that would have equated to a rough annual yield of around 2% at the time for an investor who picked up CSL back then. But if that investor held those CSL shares until today, the yield they would have gotten on their original investment would be around 4% today with CSL's dividend growth.

That's the power of a compounding growth rate. If CSL continues to increase its dividends by an average of 10.25% every year, that yield-on-cost will only grow larger, and exponentially so, in the years ahead.

So although a 1.04% trailing dividend yield might look a little paltry, CSL's history of strong dividend growth proves that sometimes it's not just size that matters.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »